Breast Cancer: Is a Clinical Trial Right For You?Responsiveness, or sensitivity to change, is an important indicator of the validity of a measurement instrument. The purpose of this study was to evaluate the responsiveness of the Multidimensional Quality of Life Questionnaire for Persons with...
91.1% and 86.6% of the patients assessed as excellent or fine cosmetic state respectively.Conclusion Breast conserving therapy for early stage breast cancer is feasible in China,with no ominous effect on the survival and recurrence rate.Breast conserving therapy is able to improve not only the ...
6,8 Methods Study Protocol The trial protocol is available in Supplement 1. This was a prospective clinical trial sponsored by the National Cancer Institute (NCI) that was coordinated by the Eastern Cooperative Oncology Group (ECOG) and subsequently ECOG-ACRIN Cancer Research Group and approved by...
Patritumab deruxtecan (HER3-DXd) is a promising therapy for breast cancer, targeting HER3. Here, the authors analyse the genomic factors that affect the response to HER3-DXd in patients with early-stage HER2-negative breast cancer as part of the SOLTI-1805 TOT-HER3 clinical trial and repo...
The TARGIT-A trial reported risk-adapted targeted intraoperative radiotherapy (TARGIT-IORT) during lumpectomy for breast cancer to be as effective as whole-breast external beam radiotherapy (EBRT). Here, we present further detailed analyses. In total, 22
Findings In this phase 1 nonrandomized clinical trial of 66 patients with advanced-stage ERBB2-positive breast cancer, a majority grade 1/2 adverse events were generated for all doses. Patients in arms 2 (100 μg) and 3 (500 μg) had higher magnitude ICD T-cell levels than those in ...
may be out of your network. There are also prescription drugs that may not be covered by your health plan. The financial hardship brought about by cancer treatment forces some survivors to return to work in order to avoid going into debt, according toresearch in theJournal of Clinical ...
new clinical trial. The FDA had just approved a new treatment protocol, and I was one of the first patients who would be going through this new protocol. And that felt really good, because I felt like certainly she understood the gravity but also the sense of "we can help you with ...
BRCA1 and BRCA2 are tumor suppressor genes that have been linked to inherited susceptibility of breast cancer. Germline BRCA1/2 pathogenic or likely pathogenic variants (gBRCAm) are clinically relevant for treatment selection in breast cancer because the
Trial Registration ClinicalTrials.gov identifier: NCT01375842 Introduction Patients with triple-negative breast cancer (TNBC) have a worse prognosis than those with other breast cancer subtypes.1-4 The median overall survival (OS) of patients with metastatic TNBC (mTNBC) is 8 to 13 months.4,5 Ch...